cadonilimab + albumin-paclitaxel + cisplatin + fluorouracil

This is a combination regimen consisting of four agents: - **Cadonilimab** is a first-in-class bispecific monoclonal antibody targeting both PD-1 and CTLA-4, developed to enhance antitumor immune responses by blocking inhibitory signals in T cells. It has demonstrated efficacy in several solid tumors, including cervical cancer and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Cadonilimab's unique tetravalent structure and Fc modifications facilitate tumor-specific accumulation and reduce off-target toxicity[1][2][3]. - **Albumin-paclitaxel** (also known as nab-paclitaxel) is an albumin-bound formulation of paclitaxel, a microtubule inhibitor that disrupts cell division. - **Cisplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. - **Fluorouracil** (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. This combination leverages the synergistic effects of immunotherapy with cytotoxic chemotherapy for enhanced antitumor activity. The regimen has been investigated primarily for advanced or metastatic solid tumors such as cervical cancer and gastric/GEJ adenocarcinoma[2][3].